RETRA

• Description :

  RETRA is a mutant p53-dependent activator of p73 that suppresses mutant p53-bearing cancer cells. RETRA increases the expression level of p73, and a release of p73 from the blocking complex with mutant p53, which produces tumor-suppressor effects[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  MDM-2/p53

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/retra.html

• Purity :

  99.42

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=C(C(CSC2=NCCS2)=O)C=C1O

• Molecular Formula :

  C11H11NO3S2

• Molecular Weight :

  269.34

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]J E Kravchenko, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 2008 Apr 29;105 (17) :6302-7.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1036069-26-7]